Skip to content

Advertisement

Open Access

Application of the international league against rheumatism classification criteria for systemic juvenile idiopathic arthritis as a prognostic factor in patients with adults-onset Still’s disease

Pediatric Rheumatology201816:9

https://doi.org/10.1186/s12969-018-0225-1

Received: 9 January 2018

Accepted: 18 January 2018

Published: 25 January 2018

Abstract

Background

Adult-onset Still’s disease (AOSD) is an adult form of systemic juvenile idiopathic arthritis (JIA) that differs from the latter in its classification. This study evaluated the concordance between the International League Against Rheumatism (ILAR) criteria for systemic JIA and the Yamaguchi criteria and then compared their possible prognostic value in patients with AOSD.

Methods

In a retrospective review of 169 adults with suspected AOSD, patients were classified according to the Yamaguchi or ILAR criteria. Then the concordance in cross-referencing the other group with the different criteria was investigated and the sensitivity and specificity of each set of criteria were determined. Disease activity markers in AOSD patients were correlated with positivity according to both systems.

Results

Concordance was good in patients with suspected AOSD (k = 0.7144, p <  0.001) and low in those with a diagnosis of AOSD (k = 0.3787, p <  0.001). The sensitivity of the ILAR criteria in AOSD patients was 0.8864 (95% confidence interval (CI): 0.8322–0.9405), and the specificity was 0.7838 (0.6511, 0.9164). Positivity according to the ILAR criteria correlated with the systemic score (r = 0.763, p <  0.0001) and C-reactive protein levels (r = 0.183, p = 0.0356) and was associated with a relapse (odds ratio: 1.589, 95% CI: 1.043–2.421), macrophage activation syndrome (MAS; odds ratio: 1.993, 95% CI: 1.218–3.263) and care in the intensive care unit (ICU; odds ratio: 2.087, 95% CI: 1.086–4.011).

Conclusions

In AOSD patients, there is fair concordance between the Yamaguchi and ILAR criteria for systemic JIA. Positive ILAR criteria may be useful for identifying AOSD patients at high risk for relapse, MAS and the need for ICU care. Further studies including larger populations from several centers are needed to confirm our results regarding the utility of the ILAR criteria in AOSD patients.

Keywords

Adult-onset Still’s diseaseSystemic juvenile idiopathic arthritisYamaguchi criteriaILAR criteria

Background

Still’s disease is a systemic form of juvenile idiopathic arthritis (JIA), the etiology and pathogenesis of which are unknown. Systemic JIA is a cause of fever of unknown origin (FUO) and it is accompanied by several systemic manifestations, such as arthritis, an evanescent rash, and serositis. A cohort of 14 adults who presented with the same symptoms as JIA patients was described in 1971, and the name adult-onset Still’s disease (AOSD) was proposed [1]. Although the adult and pediatric diseases are considered parts of the same spectrum, the diagnosis of one or the other depends on the age at onset. Individuals presenting at the age of 16 years and older are diagnosed with AOSD; younger individuals are diagnosed with systemic JIA [2, 3]. However, there are differences between JIA and AOSD, such as a higher seasonality in the former and a higher rate of pharyngitis in the latter [4]. A recent study compared the cytokine profiles of patients with AOSD and systemic JIA [5]. Among the shared features was a significant increase in interleukin 18 (IL-18) levels. Differences between the IL-6- and IL-18-based cytokine profiles may be responsible for the different clinical manifestations of JIA and AOSD and suggest the presence of two distinct subgroups within a single disease category [6].

AOSD is often difficult to diagnose because patients may present with several nonspecific symptoms and there are no serologic biomarkers of the disease. While there are several sets of clinical criteria for the classification of AOSD, those of Yamaguchi are used most widely and consist of fever, arthralgia, typical rash, and leukocytosis as major criteria, and sore throat, lymphadenopathy or splenomegaly, liver dysfunction, and the absence of rheumatoid factor (RF) and antinuclear antibody (ANA) as minor criteria [7]. Some manifestations are related to an unfavorable outcome after a chronic disease course and a prolonged period of time until clinical remission, such as typical rash, root joint arthritis, and polyarthritis [8].

AOSD and systemic JIA are considered similar diseases with a shared pathogenesis and gene expression profile, but they are difficult to classify according to the criteria currently available [5, 7, 9]. Among the various clinical criteria for diagnosing AOSD, the Yamaguchi criteria are commonly used in clinical practice, and are the most widely cited; however, they require the prior exclusion of neoplasms, infections, and autoimmune diseases mimicking AOSD [7, 10, 11]. The International League Against Rheumatism (ILAR) first proposed the term JIA, which includes all forms of arthritis that onset before the age of 16 years, persist for more than 6 weeks, and are of unknown origin [12, 13]. Although the ILAR classification of JIA is widely used, it has the limitation of being an incomplete system and new criteria have been proposed for the classification of JIA, including systemic onset [14, 15]. One study evaluated the efficacy of substituting adult diagnostic criteria in the evaluation of pediatric patients with suspected systemic JIA [16]. The results suggested that the Yamaguchi criteria can be useful for the subset of patients in the pre-arthritic phase of the disease. However, few studies have examined the utility of the ILAR criteria for the classification of patients with AOSD. Thus, in this retrospective study, we assessed the compatibility of the ILAR criteria for systemic JIA when applied to patients with AOSD. Conversely, we asked whether the ILAR criteria could be used to diagnose, evaluate disease activity, and predict the prognosis in patients with AOSD.

Methods

Patients

We identified 191 patients within the Ajou University Hospital computer system with the diagnostic code for AOSD; 22 of these patients were excluded from this study because of missing or insufficient data. We retrospectively reviewed 169 patients with suspected AOSD at the time of the initial visit to Ajou University Hospital between 2001 and 2017. During the diagnostic evaluation, 37 patients were diagnosed with another disease, including viral infection, palindromic rheumatism, lupus-like disease, and Kikuchi’s disease. Inclusion in the diagnosis of AOSD required (1) a diagnosis code of AOSD retained by the referring physician at the last follow-up; (2) a diagnosis of AOSD retained by the investigator (H.-A. K.); and (3) meeting none of the classification criteria for other immune-mediated inflammatory diseases previously described [10]. The 132 remaining patients with a diagnosis of AOSD were compared with the 37 patients with other diagnoses. All enrolled patients with five or more of the Yamaguchi criteria (and fulfilling at least two major criteria) were classified after excluding infections, malignancies (especially malignant lymphoma), and other rheumatic diseases [7]. The major and minor Yamaguchi criteria are as follows. The major criteria are (1) fever of at least 39 °C for at least 1 week, (2) arthralgia or arthritis for at least 2 weeks, (3) non-pruritic salmon-colored rash on the trunk/extremities, and (4) granulocytic leukocytosis (10,000/mL or greater). The minor criteria are (1) sore throat, (2) lymphadenopathy, (3) hepatomegaly or splenomegaly, (4) abnormal liver function tests, and (5) negative in tests for RF and ANA. Then, these patients were reclassified using the ILAR criteria for systemic JIA [12] and the concordance between the ILAR and Yamaguchi criteria was assessed. A daily fever exceeding 39 °C for at least 2 weeks or arthritis in one or more joints lasting for at least 6 weeks accompanied by one or more of the following: (1) evanescent erythematous rash, (2) generalized lymph node enlargement, (3) hepatomegaly or splenomegaly, and (4) serositis. We also evaluated the sensitivity and specificity of the ILAR criteria. This study was approved by the Institutional Review Board of our hospital (AJIRB-MED-MED-17-297).

Variables

All clinical data were retrieved from patient medical records stored in the hospital’s database. Clinical characteristics, including age, sex, clinical symptoms, follow-up period, organ involvement and extent, treatment, and outcome were evaluated. Each patient underwent a series of laboratory tests, including a complete blood count (CBC) and determination of the erythrocyte sedimentation rate (ESR) and levels of C-reactive protein (CRP), RF, ANA, ferritin, albumin, lactate dehydrogenase (LDH), and complement factors. AOSD disease activity was evaluated using the method of Pouchot et al., which assigns a score from 0 to 12 and adds 1 point for each of the following manifestations: fever, typical rash, pleuritis, pneumonia, pericarditis, hepatomegaly or abnormal liver function tests, splenomegaly, lymphadenopathy, leukocytosis ≥15,000/mm2, sore throat, myalgia, and abdominal pain [8]. Patients were treated in four steps: 1) patients used only low-dose corticosteroids or nonsteroidal anti-inflammatory drugs (NSAIDs); 2) high-dose corticosteroids without disease-modifying antirheumatic drugs (DMARDs); 3) DMARDs used regardless of the use of corticosteroids; and 4) patients were treated with corticosteroids, as well as tumor necrosis factor (TNF) inhibitors, IL-6 blockade or intravenous immunoglobulin (IVIG), regardless of the use of DMARDs (Fig. 1).
Fig. 1

A diagram for 4-step treatment schedule in patients with adult-onset Still’s disease (AOSD). IVIG, intravenous immunoglobulin; IL-1, interleukin-1

Statistical analysis

The data are expressed as the mean ± standard deviation (SD). A P value <  0.05 was considered to indicate statistical significance. The sensitivity and specificity of the two sets of diagnostic criteria were tested in patients diagnosed with AOSD group and in the non-AOSD group. The agreement between the Yamaguchi and ILAR criteria was assessed according to the kappa (k) value: a k-value > 0.8 indicated excellent agreement, 0.61–0.8 meant good agreement, 0.21–0.4 indicated fair agreement, and < 0.2 was considered poor agreement [17]. A multivariate analysis of the significant markers was performed to determine those that were independently associated with the prognosis of AOSD. A Pearson correlation test was used to determine the correlation between ESR, CRP, ferritin, and leukocyte counts, as disease activity markers, and the Yamaguchi and ILAR criteria. All statistical analyses were two-sided and were carried out using SAS statistical software, ver. 9.4 (SAS Institute).

Results

Characteristics of the study population

Table 1 shows the clinical characteristics of the 169 patients seen at the hospital for suspected AOSD. Within this group, 132 patients were diagnosed with AOSD and 37 were diagnosed with another disease. In total, 12 patients were diagnosed with palindromic rheumatism, 11 with lupus-like disease, 4 with viral exanthema, 2 each with drug eruptions, Kikuchi’s disease, and systemic lupus erythematosus, and 1 each with breast cancer, thyroid cancer, human immunodeficiency virus infection, and hypereosinophilic syndrome. The main clinical features of the 169 patients were fever (98%), maculopapular skin rash (76%), arthralgia (89%), and arthritis (48%), which appeared more frequently in the AOSD group than in non-AOSD patients. The frequencies of other clinical symptoms, such as sore throat and lymphadenopathy, were not significantly different between the two groups. Mean leukocyte and neutrophil counts were significantly higher in AOSD patients (p <  0.001), who also had higher ferritin (p = 0.002), ESR (p <  0.001), and CRP (p < 0.001) levels. Patients with AOSD were treated with corticosteroids (95%), nonsteroidal anti-inflammatory drugs (83%), methotrexate (52%), hydroxychloroquine (31%), IVIG (19%), a TNF inhibitor (6%), and IL-6 blockade (3%). During the follow-up period, 35 patients (27%) had disease relapse, 11 patients (8%) were treated in the intensive care unit (ICU), and 4 (3%) died (Table 2). Of the 134 AOSD patients, 17 (13%) were diagnosed with macrophage activation syndrome (MAS). Three patients died of pneumonia with sepsis during the treatment, and one patient died of fulminant hepatitis related to AOSD.
Table 1

Demographic and baseline characteristics of patients with suspected adult-onset Still’s disease (AOSD)

Characteristics

AOSD suspected,

but not diagnosed(N = 37)

AOSD patients(N = 132)

P-value

Age (year)

39.4 ± 12.8

41.9 ± 15.9

0.37

Sex (Male)

15 (41%)

38 (29%)

0.17

Fever

29 (78%)

130 (98%)

<.001

Sore throat

11 (30%)

71 (54%)

0.010

Maculopopular skin rash

12 (32%)

102 (77%)

<.001

Lymphadenopathy

5 (14%)

45 (34%)

0.015

Splenomegaly

4 (11%)

29 (22%)

0.130

Hepatomegaly

2 (5%)

17 (13%)

0.200

Pericarditis

0 (0%)

11 (8%)

0.069

Pleuritis

0 (0%)

11 (8%)

0.069

Arthralgia

28 (76%)

117 (89%)

0.046

Arthritis

9 (24%)

64 (48%)

0.009

Hemoglobin, g/dL

12.5 ± 0.2

11.4 ± 0.1

<.001

Leukocytes, /μL

7295.1 ± 523.5

14,708.8 ± 599.3

<.001

Neutrophils, /μL

4714.7 ± 451.3

12,734.8 ± 594.8

<.001

lymphocyte, /μL

1838.0 ± 154.6

1100.9 ± 48.0

<.001

Platelets, ×  103 μL

274.0 ± 16.2

301.1 ± 11.8

0.26

ESR, mm/h

40.4 ± 5.2

64.8 ± 2.6

<.001

CRP, mg/dL

4.3 ± 1.1

11.6 ± 0.7

<.001

AST, mg/dL

56.5 ± 17.4

93.3 ± 17.4

0.065

ALT, mg/dL

66.7 ± 21.7

94.2 ± 21.7

0.28

Ferritin, mg/dL

721.4 ± 246.0

6007.6 ± 887.3

0.002

LDH, mg/dL

334.0 ± 52.8

593.5 ± 103.0

0.21

ANA positivity

8 (29%)

21 (17%)

0.16

RF positivity

3 (9%)

10 (8%)

0.85

Systemic score

2.6 ± 0.2

5.0 ± 0.1

<.0001

AOSD adult-onset Still’s disease, ESR erythrocyte sedimentation rate, CRP C-reactive protein, AST aspartate transaminase, ALT alanine transaminase, LDH lactate dehydrogenase, ANA antinuclear antibody, RF rheumatoid factor. All values are presented as the number (%) or the mean ± SE except the age as the mean ± SD. Systemic scores (0–12) were obtained using the method described by Pouchot et al. [7], with 1 point assigned for each of the following manifestations: fever, typical rash, pleuritis, pneumonia, pericarditis, hepatomegaly or abnormal liver function tests, splenomegaly, lymphadenopathy, leukocytosis ≥ 15,000/mm2, sore throat, myalgia, and abdominal pain

Table 2

Treatment and prognosis of the patients with adult-onset Still’s disease (AOSD) during follow-up

 

AOSD patients(N = 132)

 

AOSD patients(N = 132)

Medication

 

Prognosis

 

NSAIDs

109 (83%)

Relapse

35 (27%)

Corticosteroid

126 (95%)

MAS

17 (13%)

DMARD

88 (67%)

ICU

11 (8%)

HCQ

41 (31%)

Death

4 (3%)

Azathioprine

18 (14%)

Treatment step

 

Sulfasalazine

11 (8%)

1

1 (1%)

Leflunomide

7 (5%)

2

27 (20%)

Methotrexate

69 (52%)

3

70 (53%)

IVIG

25 (19%)

4

34 (26%)

TNF inhibitor

8 (6%)

  

IL-6 blockade

4 (3%)

  

AOSD adult-onset Still’s disease, NSAIDs nonsteroidal anti-inflammatory drugs, DMARD disease modifying antirheumatic drugs, HCQ hydroxychloroquine, IVIG intravenous immunoglobulin, TNF tumor necrosis factor, IL-6 interleukin-6, MAS macrophage activation syndrome, ICU intensive unit care. Values are expressed as n (%)

Concordance between Yamaguchi and ILAR criteria in patients with suspected AOSD

Concordance between the Yamaguchi and ILAR criteria in patients with suspected AOSD was good (k = 0.7144, p < 0.001) whereas in the diagnosed AOSD group it was fair (k = 0.3787, p < 0.001), and lower than that based on a comparison with all suspected AOSD patients (Table 3). Thus, overall, there was substantial concordance between the two sets of criteria. We evaluated the sensitivity and specificity of the ILAR criteria for systemic JIA in patients with suspected AOSD. The sensitivity was 0.8864, with a 95% confidence interval (CI) of 0.8322–0.9405, and the specificity was 0.7838, with a 95% CI of 0.6511–0.9164 (Table 4).
Table 3

Agreement between the Yamaguchi and International League Against Rheumatism (ILAR) criteria in patients with suspected adult-onset Still’s disease (AOSD) or with confirmed AOSD

 

Yamaguchi and ILAR criteria

All suspected AOSD

 Kappa (p-value)

0.7144 (<  0.0001)

 95% confidence interval

(0.5947, 0.8341)

AOSD-diagnosed patients

 Kappa (p-value)

0.3787 (< 0.0001)

 95% confidence interval

(0.1416, 0.6159)

The concordance between the Yamaguchi and ILAR criteria was assessed by the kappa (k) value: a k-value > 0.8 indicated excellent agreement, 0.61–0.8 meant good agreement, 0.21-0.4 indicated fair agreement, and < 0.2 was considered poor agreement

Table 4

Sensitivity and specificity of International League Against Rheumatism (ILAR) and Yamaguchi criteria in suspected adult-onset Still’s disease (AOSD) patients

Disease

ILAR criteria

Yamaguchi criteria

 

+

+

Total

AOSD patients

117

15

119

13

132

Not AOSD patients

8

29

3

34

37

Total

125

44

122

47

169

The sensitivity was 88.6%, and the specificity was 78.4%, with the ILAR criteria. The sensitivity was 90.2%, and the specificity was 91.9%, with the Yamaguchi criteria

Correlation between disease activity markers and JIA and Yamaguchi criteria positivity in AOSD patients

We evaluated correlations between the levels of disease activity markers, such as the systemic score, ESR, and CRP, and the number of positive JIA or Yamaguchi criteria in patients with AOSD. The systemic score (ρ = 0.437, p < 0.0001), leukocyte count (ρ = 0.312, p = 0.0003), ESR (ρ = 0.178, p = 0.0406), CRP level (ρ = 0.216, p = 0.0128), and LDH level (ρ = − 0.307, p = 0.0056) correlated positively and significantly with the Yamaguchi criteria. The relationships between the ILAR criteria for systemic JIA and the systemic score (ρ = 0.741, p < 0.0001), CRP level (ρ = 0.237, p = 0.0063), and albumin (ρ = − 0.281, p = 0.0011) were also significant and positive (Table 5).
Table 5

Correlation between disease activity markers and the number of positive International League Against Rheumatism (ILAR) and Yamaguchi criteria in AOSD patients

 

Yamaguchi criteria

ILAR criteria

 

ρ

P-value

ρ

P-value

Systemic score

0.437

< 0.0001

0.741

< 0.0001

Leukocytes

0.312

0.0003

−0.007

0.9369

Hemoglobin

−0.062

0.4802

−0.092

0.2953

Platelets

0.155

0.0764

−0.102

0.2461

ESR

0.178

0.0406

0.115

0.1890

CRP

0.216

0.0128

0.237

0.0063

Ferritin

0.169

0.0534

0.055

0.5274

LDH

−0.307

0.0056

−0.055

0.6290

Total bilirubin

−0.150

0.0864

−0.002

0.9798

Albumin

−0.156

0.0744

−0.281

0.0011

AST

−0.104

0.2334

−0.035

0.6891

ALT

−0.032

0.7151

−0.058

0.5064

ESR erythrocyte sedimentation rate, CRP C-reactive protein, LDH lactate dehydrogenase, AST aspartate aminotransferase, ALT alanine aminotransferase. Systemic scores (0–12) were obtained using the method described by Pouchot et al. [8], with 1 point assigned for each of the following manifestations: fever, typical rash, pleuritis, pneumonia, pericarditis, hepatomegaly or abnormal liver function tests, splenomegaly, lymphadenopathy, leukocytosis ≥ 15,000/mm2, sore throat, myalgia, and abdominal pain. The Pearson correlation statistic was used to compare the correlation between ESR, CRP, ferritin, and leukocyte counts, as disease activity markers, and the Yamaguchi and ILAR criteria

Positivity of the ILAR criteria for systemic JIA and the Yamaguchi criteria as a prognostic factor in AOSD patients

The frequencies of relapse, MAS, care in the ICU, and death were designated as prognostic factors and then the data were analyzed using the logistic regression model with the positivity of the ILAR and Yamaguchi criteria in patients with AOSD. None of the prognostic factors were significantly associated with the Yamaguchi criteria but the relationships of relapse (odds ratio = 1.712, 95% CI = 1.166–2.512), MAS (odds ratio = 1.993, 95% CI = 1.218–3.263) and ICU care (odds ratio = 2.080, 95% CI = 1.135–3.811) with the positivity of the ILAR criteria for systemic JIA in patients with AOSD were significant (Table 6).
Table 6

Positivity of the International League Against Rheumatism (ILAR) criteria and Yamaguchi criteria as a prognostic factor for death or care in the intensive care unit (ICU) in patients with adult-onset Still’s disease (AOSD). The data were analyzed using a logistic regression model

Outcome of interests

Effect

Positive Yamaguchi criteria

Positive ILAR criteria

Odds ratio estimate

95% Wald

confidence interval

Odds ratio estimate

95% Wald

confidence limits

Prognosis

 Relapse

1.295

0.729

2.298

1.589

1.043

2.421

 MAS

1.325

0.750

2.340

1.993

1.218

3.263

 ICU

1.145

0.464

2.827

2.087

1.086

4.011

 Death

0.769

0.217

2.726

0.746

0.236

2.364

AOSD adult-onset Still’s disease, MAS macrophage activation syndrome, ICU intensive unit care

Discussion

This is the first study to evaluate the ILAR criteria for systemic JIA in patients with AOSD. The results showed fair concordance between the Yamaguchi and ILAR criteria for systemic JIA in patients with AOSD. However, the positivity of the ILAR criteria may be useful for the identification of AOSD patients at high risk for relapse, association with MAS and ICU care.

Several studies have compared children and adults with Still’s disease [1820], but most have been unable to find specific differences between AOSD and systemic JIA. One study showed that nine patients with systemic JIA met the Yamaguchi criteria [19], while another detected differences with respect to articular involvement between the two groups [18]. Nonetheless, given the large number of similarities between pediatric and adult patients, the diseases can be considered to the same or at least similar. Therefore, we evaluated the sensitivity and specificity of the ILAR criteria for systemic JIA in patients with suspected AOSD. Our results showed concordance between the Yamaguchi and ILAR criteria in these patients. Among the 169 patients with suspected AOSD, Cohen’s kappa was 0.7144, indicative of substantial agreement between the two sets of criteria. When only the 132 AOSD patients were considered, Cohen’s kappa was lower (0.387), but it still supported agreement between the Yamaguchi and ILAR criteria. There was substantial concordance when the entire patient population with suspected AOSD was included, but only fair concordance when this was limited to the AOSD group. This is probably due to the fact that arthritis was more common in the AOSD group than in the non-AOSD group, but it was still present in less than 50% of cases. This may reflect the ILAR criteria requiring the presence of arthritis to diagnose a patient with systemic JIA [12]. One study has suggested that the presence of arthritis is a strict criterion, but this could lead to an unacceptable delay in diagnosis [16]. That study also showed that patients with systemic JIA may experience a significant period during which they do not have arthritis, particularly at disease onset [16]. Those authors concluded that the Yamaguchi criteria may be useful for the subset of patients in the pre-arthritic phase of the disease. As part of this process, Dr. Martini proposed a prospective research plan for establishing a new provisional classification system for JIA in the 23rd European Pediatric Rheumatology Congress [15]. In this study, our patients with AOSD had a low frequency of arthritis, which may explain the low sensitivity and specificity of the ILAR criteria in patients with AOSD.

Many recent studies have sought to identify simple markers for evaluating AOSD disease severity, activity, or prognosis. The candidate biomarkers included simple clinical laboratory markers, such as ESR, CRP, ferritin, the neutrophil to lymphocyte ratio, and procalcitonin, as well as several cytokines or chemokines, such as IL-6, IL-8, CXC motif chemokine 13, and IL-18 [5, 2123]. However, clinical laboratory markers are relatively nonspecific, and cytokine determinations are not clinically feasible. A recent study suggested that Pouchot’s systemic score could predict a poor outcome in patients with AOSD. Thus, a score > 7 and the presence of any complication, such as MAS, kidney failure, or myocarditis at diagnosis, were associated with mortality [24]. Our study evaluated the positivity of the ILAR criteria in patients with AOSD, with respect to preexisting disease activity markers and prognosis. ILAR criteria positivity correlated with the systemic scores and the levels of CRP and albumin. We were also able to demonstrate an association between positivity for the ILAR criteria and two prognostic factors, relapse and ICU care, in patients with AOSD. These results suggest that the ILAR criteria can aid the evaluation of disease activity and prediction of prognosis of AOSD. The differences between the ILAR and Yamaguchi criteria are the presence of serositis and absence of leukocytosis, sore throat, and elevated liver enzyme concentrations. Our results could be related to the presence of serositis in the ILAR criteria. Some studies suggested that serositis is a poor prognostic factor for early onset JIA or joint damage in systemic JIA [25, 26].

There were several important limitations to this study. First, because it was conducted in a single center, the data were limited and may have been subject to selection bias. Second, because we reviewed electronic medical records, some patient data may have been missing and the records of a few patient records were not available. Third, the patients who did not meet the initial screening criterion regarding the diagnostic code for AOSD were not included.

Conclusion

Despite the lack of sensitivity and specificity of the ILAR criteria for systemic JIA in the classification of AOSD, there was fair concordance between the Yamaguchi and ILAR criteria in AOSD patients. Our results indicate that the ILAR criteria can be used as an additional predictor of relapse, MAS and ICU care in AOSD patients. Further studies of larger populations from several centers are needed to confirm our results regarding the utility of the ILAR criteria in AOSD patients.

Abbreviations

ALT: 

Alanine transaminase

ANA: 

Antinuclear antibody

AOSD: 

Adult-onset Still’s disease

AST: 

Aspartate transaminase

CBC: 

Complete blood count

CI: 

Confidence interval

CRP: 

C-reactive protein

DMARD: 

Disease-modifying antirheumatic drugs

ESR: 

Erythrocyte sedimentation rate

FUO: 

Fever of unknown origin

HCQ: 

Hydroxychloroquine

ICU: 

Intensive unit care

IL-18: 

Interleukin 18

ILAR: 

International League Against Rheumatism

IVIG: 

Intravenous immunoglobulin

JIA: 

Juvenile idiopathic arthritis

k: 

kappa

LDH: 

Lactate dehydrogenase

RF: 

Rheumatoid factor

SD: 

Standard deviation

SE: 

Standard error

TNF: 

Tumor necrosis factor

Declarations

Acknowledgements

None

Funding

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI16C0992).

Availability of data and materials

All data generated or analyzed during this study are included in this article.

Authors’ contributions

JWY, EL, J-YS, J-YJ, C-HS and H-AK designed the study. JWY, J-YS and H-AK collected the data. JWY and EL analysed the data under supervision of H-AK. JWY, EL and H-AK produced the initial draft and all authors contributed to subsequent drafts and approved the final version.

Ethics approval and consent to participate

This study was approved by the Institutional Review Board of our hospital, and waved to inform the consent by the Institutional Review Board of our hospital because of retrospective study nature.

Consent for publication

Not applicable

Competing interests

No author has any potential conflict of interest with respect to the research, authorship or publication of this article.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Rheumatology, Ajou University School of Medicine, Suwon, South Korea
(2)
Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, South Korea

References

  1. Bywaters EG. Still’s disease in the adult. Ann Rheum Dis. 1971;30:121–33.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Hedrich CM, Günther C, Aringer M. Still's disease in children and adults. Z Rheumatol. 2017;76:595–608.Google Scholar
  3. de Graaff LC, ten Broek MR, Schweitzer DH. Is Still's disease still one disease? A case of adult-onset Still's disease showing accumulation in the carotids and the large vessels of the legs on positron emission tomography: CT images. Rheumatol Int. 2012;32:2487–90.View ArticlePubMedGoogle Scholar
  4. Jamilloux Y, Gerfaud-Valentin M, Martinon F, et al. Pathogenesis of adult-onset Still's disease: new insights from the juvenile counterpart. Immunol Res. 2015;61:53–62.View ArticlePubMedGoogle Scholar
  5. Inoue N, Shimizu M, Tsunoda S, et al. Cytokine profile in adult-onset Still's disease: comparison with systemic juvenile idiopathic arthritis. Clin Immunol. 2016;169:8–13.View ArticlePubMedGoogle Scholar
  6. Nigrovic PA, Raychaudhuri S, Thompson SD. Review: genetics and the classification of arthritis in adults and children. Arthritis Rheumatol. 2018;70:7–17.View ArticlePubMedGoogle Scholar
  7. Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol. 1992;19:424–30.PubMedGoogle Scholar
  8. Pouchot J, Sampalis JS, Beaudet F, et al. Adult Still's disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore). 1991;70:118–36.View ArticleGoogle Scholar
  9. Nirmala N, Brachat A, Feist E, et al. Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity. Pediatr Rheumatol Online J. 2015;13:50.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Lebrun D, Mestrallet S, Dehoux M, et al. Validation of the Fautrel classification criteria for adult-onset Still's disease. Semin Arthritis Rheum. 2018;47:578–85.Google Scholar
  11. Masson C, Le Loet X, Liote F, et al. Comparative study of 6 types of criteria in adult Still's disease. J Rheumatol. 1996;23:495–7.PubMedGoogle Scholar
  12. Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–2.PubMedGoogle Scholar
  13. Fink CW. Proposal for the development of classification criteria for idiopathic arthritides of childhood. J Rheumatol. 1995;22:1566–9.PubMedGoogle Scholar
  14. Ravelli A, Varnier GC, Oliveira S, et al. Antinuclear antibody-positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. Arthritis Rheum. 2011;63:267–75.View ArticlePubMedGoogle Scholar
  15. Martini A. It is time to rethink juvenile idiopathic arthritis classification and nomenclature. Ann Rheum Dis. 2012;71:1437–9.View ArticlePubMedGoogle Scholar
  16. Kumar S, Kunhiraman DS, Rajam L. Application of the Yamaguchi criteria for classification of "suspected" systemic juvenile idiopathic arthritis (sJIA). Pediatr Rheumatol Online J. 2012;10:40.Google Scholar
  17. Landis JR, Koch GG. An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics. 1977;33:363–74.View ArticlePubMedGoogle Scholar
  18. Lin SJ, Chao HC, Yan DC. Different articular outcomes of Still's disease in Chinese children and adults. Clin Rheumatol. 2000;19:127–30.View ArticlePubMedGoogle Scholar
  19. Luthi F, Zufferey P, Hofer MF, et al. "adolescent-onset Still's disease": characteristics and outcome in comparison with adult-onset Still's disease. Clin Exp Rheumatol. 2002;20:427–30.PubMedGoogle Scholar
  20. Uppal SS, Pande IR, Kumar A, et al. Adult onset Still's disease in northern India: comparison with juvenile onset Still's disease. Br J Rheumatol. 1995;34:429–34.View ArticlePubMedGoogle Scholar
  21. Han JH, Suh CH, Jung JY, et al. Association of CXCL10 and CXCL13 levels with disease activity and cutaneous manifestation in active adult-onset Still's disease. Arthritis Res Ther. 2015;17:260.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Seo JY, Suh CH, Jung JY, et al. The neutrophil-to-lymphocyte ratio could be a good diagnostic marker and predictor of relapse in patients with adult-onset Still's disease: a STROBE-compliant retrospective observational analysis. Medicine (Baltimore). 2017;96:e7546.View ArticleGoogle Scholar
  23. Chen DY, Lan JL, Lin FJ, et al. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. J Rheumatol. 2004;31:2189–98.PubMedGoogle Scholar
  24. Ruscitti P, Cipriani P, Masedu F, et al. Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. BMC Med. 2016;14:194.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Russo RA, Katsicas MM. Patients with very early-onset systemic juvenile idiopathic arthritis exhibit more inflammatory features and a worse outcome. J Rheumatol. 2013;40:329–34.View ArticlePubMedGoogle Scholar
  26. Sandborg C, Holmes TH, Lee T, et al. Candidate early predictors for progression to joint damage in systemic juvenile idiopathic arthritis. J Rheumatol. 2006;33:2322–9.PubMedGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement